Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.07M P/E - EPS this Y 91.90% Ern Qtrly Grth -
Income -12.1M Forward P/E -0.30 EPS next Y 55.00% 50D Avg Chg -37.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -83.00%
Dividend N/A Price/Book 0.11 EPS next 5Y - 52W High Chg -95.00%
Recommedations 1.70 Quick Ratio 4.65 Shares Outstanding 7.25M 52W Low Chg -
Insider Own 6.38% ROA -39.54% Shares Float 7.13M Beta -0.17
Inst Own 3.70% ROE -108.02% Shares Shorted/Prior 364.20K/88.89K Price 0.56
Gross Margin - Profit Margin - Avg. Volume 270,170 Target Price 12.33
Oper. Margin - Earnings Date Nov 7 Volume 93,777 Change -5.08%
About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Kiora Pharmaceuticals, Inc. News
09/21/23 Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
09/18/23 Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
09/14/23 Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
09/01/23 Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
08/29/23 Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
08/23/23 Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis
08/23/23 Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
08/22/23 Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program
08/16/23 Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
08/08/23 Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
08/03/23 Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment
08/01/23 Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
07/05/23 Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
06/23/23 Life Science Investor Forum: Presentations Now Available for Online Viewing
06/20/23 Life Science Investor Forum Agenda Announced for June 22nd
06/15/23 Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
06/14/23 Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
06/06/23 Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
06/02/23 Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
05/09/23 Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
KPRX Chatroom

User Image Stocksrockman Posted - 2 days ago

$WRNT holding above support Breaking major levels Moonday $GTEC turning up $KPRX may be a top $IDAI back to $1.50 $RDW why dip?

User Image Stocksrockman Posted - 2 days ago

$KPRX nice bounce $NFTG 19 months left of cash $GOVX waking up $WRNT MOOOOOONDAY BABY!!! Titties and money!! WOOOO! $KLR watch

User Image raspop Posted - 2 days ago

$KPRX this looks ready... keeping an eye

User Image TheButchers Posted - 3 days ago

$KPRX It’s not a great thing when you only get a momentum shift when the chairman calls it quits.

User Image Dammam Posted - 3 days ago

@joka2189 $KPRX tweaking that 0.55 now

User Image Jduffy5130 Posted - 3 days ago

$KPRX buy this and add every dip

User Image SoldTooSoon Posted - 4 days ago

$KPRX

User Image newsfile_corp Posted - 4 days ago

https://www.newsfilecorp.com/release/181329 $KPRX Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney W

User Image Stock_Titan Posted - 4 days ago

$KPRX Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-appoints-praveen-tyle-ph-d-as-new-chairman-xb8zoo3ldb4a.html

User Image LowFloatCap Posted - 5 days ago

$KPRX like this slow and steady upward moving with a little volume. It may surprise us at some point. Put it on your radar

User Image newsfile_corp Posted - 1 week ago

https://www.newsfilecorp.com/release/180828 $KPRX Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in

User Image Stock_Titan Posted - 1 week ago

$KPRX Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-completes-last-patient-last-visit-in-phase-1b-jkx6vfv7b5kd.html

User Image AnnieBullBucks Posted - 1 week ago

$KPRX

User Image Rasco Posted - 1 week ago

$KPRX just averaged down to 1.27 & feel ok about it. How long do I have to hold for a 5-bagger😄💲

User Image newsfile_corp Posted - 1 week ago

https://www.newsfilecorp.com/release/180596 $KPRX Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academ

User Image Stock_Titan Posted - 1 week ago

$KPRX Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-to-present-topline-results-from-the-abacus-jb9wm9iv62iy.html

User Image SoldTooSoon Posted - 1 week ago

$KPRX what is going to get this SP moving, dead in the water..

User Image Bgirl_smirk Posted - 2 weeks ago

$kprx monthly flipped nice float $Lase let’s see might get some dips

User Image Stocksrockman Posted - 2 weeks ago

$MOB MOONDAY IS TOMORROW! $LASE is very appealing here $KPRX may be moving into uptrend $TOPS appealing here as well $ATNF algo locked

User Image Madmaxium Posted - 2 weeks ago

$KPRX - about too launch!!

User Image SoldTooSoon Posted - 2 weeks ago

$KPRX the fact that this company's market cap is only 3.2m is pretty ridiculous, the value of the IP of what they have developed should easily be worth significantly more to their competitors, even the 2$ price target seems laughably low, 15m market cap is the target?

User Image apache007 Posted - 2 weeks ago

$KPRX 1$ pt soon next FWBI

User Image profitraider Posted - 2 weeks ago

$KPRX when you had complete failure success is right around the corner 🤷‍♂️

User Image Jduffy5130 Posted - 2 weeks ago

$KPRX when do shareholders ever agree to do a R/S ?

User Image Stocks204 Posted - 2 weeks ago

$KPRX 🚀 soon

User Image TheButchers Posted - 3 weeks ago

@SoldTooSoon $KPRX to approve management compensation that is basically an anti dilutive measure and give management the ability to pay off Lincoln Park to satisfy their sweetheart deal terms for new capital. In other words more free give aways and dilution due to their incompetence.

User Image TheButchers Posted - 3 weeks ago

$KPRX Nobody cares anymore or at least not hardly enough people care. Vote no on everything and get a new Board. Company is worth about 1/250th of when CEO took over and it hasn’t been that long. “A quorum consists of one third of the voting power of the outstanding shares of the Company entitled to vote generally in the election of directors. There were fewer than one third of the voting power of outstanding shares entitled to vote present, either in person or by proxy at the meeting. The Special Meeting therefore had no quorum, and the meeting was adjourned to 8:30 a.m. Pacific Time on Wednesday, September 27, 2023 at the offices of the Company at 332 Encinitas Blvd., Suite 102, Encinitas, CA 92024 to allow additional time for the Company's stockholders to vote on the proposals set forth in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission (the "SEC") on July 21, 2023.”

User Image risenhoover Posted - 3 weeks ago

$KPRX / Kiora Pharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 31, 2023 KIORA PHARMACEUTICA https://fintel.io/sf/us/kprx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image SoldTooSoon Posted - 3 weeks ago

$KPRX what are they asking to vote on for the proxy? Anything of substance beyond voting the board or standard stuff?

User Image newsfile_corp Posted - 3 weeks ago

https://www.newsfilecorp.com/release/179291 $KPRX Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 #Biotechno

Analyst Ratings
HC Wainwright & Co. Buy Aug 24, 23
HC Wainwright & Co. Buy Aug 14, 23
Maxim Group Buy Aug 9, 23
HC Wainwright & Co. Buy May 12, 23
HC Wainwright & Co. Buy Mar 24, 23
Maxim Group Buy Feb 9, 23
HC Wainwright & Co. Buy Feb 8, 23
Ladenburg Thalmann Buy Feb 8, 23
Ladenburg Thalmann Buy Aug 25, 22